OPKO Health (NASDAQ:OPK) versus Viemed Healthcare (NASDAQ:VMD) Head-To-Head Contrast

Viemed Healthcare (NASDAQ:VMD) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and target prices for Viemed Healthcare and OPKO Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0	3	1	0	2.25
OPKO Health	1	3	1	1	2.33

Viemed Healthcare currently has a consensus target price of $14.00, suggesting a potential upside of 53.34%. OPKO Health has a consensus target price of $1.55, suggesting a potential downside of 0.64%. Given Viemed Healthcare’s higher probable upside, analysts clearly believe Viemed Healthcare is more favorable than OPKO Health.

Risk and Volatility

Viemed Healthcare has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

Profitability

This table compares Viemed Healthcare and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	4.81%	10.16%	7.22%
OPKO Health	-12.40%	-5.88%	-3.83%

Insider & Institutional Ownership

74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 20.6% of Viemed Healthcare shares are owned by insiders. Comparatively, 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Viemed Healthcare and OPKO Health”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$301.61 million	1.15	$14.93 million	$0.36	25.36
OPKO Health	$606.90 million	1.92	-$225.68 million	($0.09)	-17.33

Viemed Healthcare has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

Viemed Healthcare beats OPKO Health on 8 of the 14 factors compared between the two stocks.

About Viemed Healthcare

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.